Evidence map›Paper›PMID 24492306›Full record

ArticlemAbs

Multiplexed screening of natural humoral immunity identifies antibodies at fine specificity for complex and dynamic viral targets.

Krista M McCutcheon, Julia Gray, Natalie Y Chen, Keyi Liu, Minha Park, Stote Ellsworth, Ralph A Tripp, S Mark Tompkins, Scott K Johnson, Shelly Samet and 2 more

Open access · goldAbstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. A Native Human Monoclonal Antibody Targeting HCMV gB (AD-2 Site I).International journal of molecular sciences · 2018
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Krista M McCutcheonGilead Sciences; Foster City, CA USA.
Julia GrayArchaogen; South San Francisco, CA USA.
Natalie Y ChenTrellis Biosciences; South San Francisco, CA USA.
Keyi LiuTrellis Biosciences; South San Francisco, CA USA.
Minha ParkCrystal Bioscience; Emeryville, CA USA.
Stote EllsworthTrellis Biosciences; South San Francisco, CA USA.
Ralph A TrippUniversity of Georgia; Athens, GA USA.
S Mark TompkinsUniversity of Georgia; Athens, GA USA.
Scott K JohnsonUniversity of Georgia; Athens, GA USA.
Shelly SametUniversity of Georgia; Athens, GA USA.
Lenore PereiraUniversity of California; San Francisco, CA USA.
Lawrence M KauvarCrystal Bioscience; Emeryville, CA USA.
Kaiser Permanente South San Francisco Medical Center · USPiedmont Athens Regional · USGilead Sciences (United States) · USUniversity of California, San Francisco · USUniversity of Georgia · US

Funding

Fetal HCMV Infection: Role of the Human PlacentaR01AI046657 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PEREIRA, LENORE PALMA · 2000 to 2017
$5.9M
Therapeutic Antibodies for CMVR44AI102396 · NIAID · TRELLIS BIOSCIENCE, INC. · PI KAUVAR, LAWRENCE MICHAEL · 2012 to 2015
$3.3M
NIAID NIH HHS R01 AI046657NIAID NIH HHS R44 AI102396
6 · The paper itself

Abstract

Viral entry targets with therapeutic neutralizing potential are subject to multiple escape mechanisms, including antigenic drift, immune dominance of functionally irrelevant epitopes, and subtle variations in host cell mechanisms. A surprising finding of recent years is that potent neutralizing antibodies to viral epitopes independent of strain exist, but are poorly represented across the diverse human population. Identifying these antibodies and understanding the biology mediating the specific immune response is thus difficult. An effective strategy for meeting this challenge is to incorporate multiplexed antigen screening into a high throughput survey of the memory B cell repertoire from immune individuals. We used this approach to discover suites of cross-clade antibodies directed to conformational epitopes in the stalk region of the influenza A hemagglutinin (HA) protein and to select high-affinity anti-peptide antibodies to the glycoprotein B (gB) of human cytomegalovirus. In each case, our screens revealed a restricted VH and VL germline usage, including published and previously unidentified gene families. The in vivo evolution of paratope specificity with optimal neutralizing activity was understandable after correlating biological activities with kinetic binding and epitope recognition. Iterative feedback between antigen probe design based on structure and function information with high throughput multiplexed screening demonstrated a generally applicable strategy for efficient identification of safe, native, finely tuned antibodies with the potential for high genetic barriers to viral escape.

Indexed as

Antibodies, BlockingAntibody AffinityAntigens, ViralB-LymphocytesB-Lymphocyte SubsetsCell LineCytomegalovirusCytomegalovirus InfectionsEpitopesHemagglutinin Glycoproteins, Influenza VirusHigh-Throughput Screening AssaysHumansImmune EvasionImmunity, HumoralImmunity, InnateImmunologic MemoryAntibodies, BlockingAntigens, ViralEpitopesglycoprotein B, SimplexvirusHemagglutinin Glycoproteins, Influenza VirusViral Envelope Proteinsbroadly protective antibodiescytomegalovirusfusionhuman antibodiesimmunoglobulin germlineinfluenzamonoclonal antibodiesneutralizing antibodiesviral epitopes

Identifiers

PMID24492306
PMCPMC3984334
OpenAlexW2070296289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.